Impact of Chronic Cannabis Use on Auditory Mismatch Negativity Generation in Schizophrenia Patients

Patrik Roser; Eva-Maria Pichler; Benedikt Habermeyer; Wolfram Kawohl; Georg Juckel

doi:10.1055/a-0573-9866

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2019; 52(03): 126-133
DOI: 10.1055/a-0573-9866

Original Paper

Impact of Chronic Cannabis Use on Auditory Mismatch Negativity Generation in Schizophrenia Patients

Patrik Roser

¹Klinik für Psychiatrie, Psychotherapie und Präventivmedizin, LWL-Universitätsklinikum Bochum, Ruhr-Universität Bochum, Germany

²Zentrum für Abhängigkeitserkrankungen, Psychiatrische Dienste Aargau AG, Akademisches Lehrspital der Universität Zürich, Switzerland

,

Eva-Maria Pichler

³Bereich Psychiatrie und Psychotherapie, Psychiatrische Dienste Aargau AG, Akademisches Lehrspital der Universität Zürich, Switzerland

,

Benedikt Habermeyer

²Zentrum für Abhängigkeitserkrankungen, Psychiatrische Dienste Aargau AG, Akademisches Lehrspital der Universität Zürich, Switzerland

,

Wolfram Kawohl

³Bereich Psychiatrie und Psychotherapie, Psychiatrische Dienste Aargau AG, Akademisches Lehrspital der Universität Zürich, Switzerland

,

Georg Juckel

¹Klinik für Psychiatrie, Psychotherapie und Präventivmedizin, LWL-Universitätsklinikum Bochum, Ruhr-Universität Bochum, Germany

› Author Affiliations

Abstract

Introduction Cannabis use disorders (CUD) are highly prevalent among patients with schizophrenia (SCZ). Deficient mismatch negativity (MMN) generation is a characteristic finding in SCZ patients and cannabis users. This study therefore examined the effects of CUD on MMN generation in SCZ patients.

Methods Twenty SCZ − CUD patients, 21 SCZ+CUD patients, and 20 healthy controls (HC) were included in this study. MMN to frequency and duration deviants was elicited within an auditory oddball paradigm and recorded by 32 channel EEG.

Results As expected, SCZ − CUD patients showed reduced frontocentral MMN amplitudes to duration deviants compared to HC. Interestingly, SCZ+CUD patients demonstrated greater MMN amplitudes to duration deviants compared to SCZ − CUD patients at central electrodes with no differences compared to HC.

Discussion These results demonstrate that comorbid cannabis use in SCZ patients might be associated with superior cognitive functioning. It can be assumed that the association between cannabis use and better cognitive performance may be due to a subgroup of cognitively less impaired SCZ patients characterized by lower genetic vulnerability for psychosis.

Key words

cannabis - mismatch negativity - event-related potentials - schizophrenia - comorbidity

Full Text

References

References
1 D’Souza DC. Cannabinoids and psychosis. Int Rev Neurobiol 2007; 78: 289-326
2 Henquet C, Krabbendam L, Spauwen J. et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005; 330: 11
3 Kuepper R, van Os J, Lieb R. et al. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ 2011; 342: d738
4 Arseneault L, Cannon M, Witton J. et al. Causal association between cannabis and psychosis: Examination of the evidence. Br J Psychiatry 2004; 184: 110-117
5 D’Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: Human studies. Eur Arch Psychiatry Clin Neurosci 2009; 259: 413-431
6 Broyd SJ, Greenwood LM, Croft RJ. et al. Chronic effects of cannabis on sensory gating. Int J Psychophysiol 2013; 89: 381-389
7 Broyd SJ, Greenwood LM, van Hell HH. et al. Mismatch negativity and P50 sensory gating in abstinent former cannabis users. Neural Plast 2016; 2016: 6526437
8 Gallinat J, Rentzsch J, Roser P. Neurophysiological effects of cannabinoids: Implications for psychosis research. Curr Pharm Des 2012; 18: 4938-4949
9 Greenwood LM, Broyd SJ, Croft R. et al. Chronic effects of cannabis on the auditory mismatch negativity. Biol Psychiatry 2014; 75: 449-458
10 Juckel G, Roser P, Nadulski T. et al. Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity. Schizophr Res 2007; 97: 109-117
11 Roser P, Juckel G, Rentzsch J. et al. Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. Eur Neuropsychopharmacol 2008; 18: 569-577
12 Roser P, Della B, Norra C. et al. Auditory mismatch negativity deficits in long-term heavy cannabis users. Eur Arch Psychiatry Clin Neurosci 2010; 260: 491-498
13 Solowij N, Michie PT. Cannabis and cognitive dysfunction: Parallels with endophenotypes of schizophrenia?. J Psychiatry Neurosci 2007; 32: 30-52
14 Lorenzetti V, Solowij N, Yücel M. The role of cannabinoids in neuroanatomic alterations in cannabis users. Biol Psychiatry 2016; 79: e17-e31
15 Martín-Santos R, Fagundo AB, Crippa JA. et al. Neuroimaging in cannabis use: A systematic review of the literature. Psychol Med 2010; 40: 383-398
16 Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77: 299-318
17 Solowij N, Stephens RS, Roffman RA. et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002; 287: 1123-1131
18 Broyd SJ, van Hell HH, Beale C. et al. Acute and chronic effects of cannabinoids on human cognition – a systematic review. Biol Psychiatry 2016; 79: 557-567
19 Koskinen J, Löhönen J, Koponen H. et al. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: A meta-analysis. Schizophr Bull 2010; 36: 1115-1130
20 D’Souza DC, Abi-Saab WM, Madonick S. et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biol Psychiatry 2005; 57: 594-608
21 Bersani G, Orlandi V, Kotzalidis GD. et al. Cannabis and schizophrenia: Impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci 2002; 252: 86-92
22 Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51: 273-279
23 DeRosse P, Kaplan A, Burdick KE. et al. Cannabis use disorders in schizophrenia: Effects on cognition and symptoms. Schizophr Res 2010; 120: 95-100
24 Yücel M, Bora E, Lubman DI. et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: A meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull 2012; 38: 316-330
25 Jockers-Scherübl MC, Wolf T, Radzei N. et al. Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1054-1063
26 Erickson MA, Ruffle A, Gold JM. A meta-analysis of mismatch negativity in schizophrenia: From clinical risk to disease specificity and progression. Biol Psychiatry 2016; 79: 980-987
27 Näätänen R, Kähkönen S. Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: A review. Int J Neuropsychopharmacol 2009; 12: 125-135
28 Umbricht D, Krljes S. Mismatch negativity in schizophrenia: A meta-analysis. Schizophr Res 2005; 76: 1-23
29 Murphy JR, Rawdon C, Kelleher I. et al. Reduced duration mismatch negativity in adolescents with psychotic symptoms: Further evidence for mismatch negativity as a possible biomarker for vulnerability to psychosis. BMC Psychiatry 2013; 13: 45
30 Umbricht DS, Bates JA, Lieberman JA. et al. Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia. Biol Psychiatry 2006; 59: 762-772
31 Umbricht D, Koller R, Schmid L. et al. How specific are deficits in mismatch negativity generation to schizophrenia?. Biol Psychiatry 2003; 53: 1120-1131
32 Näätänen R. The mismatch negativity: A powerful tool for cognitive neuroscience. Ear Hear 1995; 16: 6-18
33 Näätänen R, Paavilainen P, Tiitinen H. et al. Attention and mismatch negativity. Psychophysiology 1993; 30: 436-450
34 Roser P, Haussleiter IS, Chong HJ. et al. Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia. Psychopharmacology (Berl) 2011; 218: 611-620
35 Kedzior KK, Badcock JC, Martin-Iverson MT. Validity and consistency of self-reports regarding substance use in general research volunteers, including regular cannabis users and schizophrenia patients. Subst Use Misuse 2006; 41: 743-750
36 Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64: 663-667
37 Umbricht D, Schmid L, Koller R. et al. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: Implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 2000; 57: 1139-1147
38 Picton TW, Bentin S, Berg P. et al. Guidelines for using human event-related potentials to study cognition: Recording standards and publication criteria. Psychophysiology 2000; 37: 127-152
39 Pope Jr HG, Gruber AJ, Hudson JI. et al. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 58: 909-915
40 Todd J, Michie PT, Schall U. et al. Deviant matters: Duration, frequency, and intensity deviants reveal different patterns of mismatch negativity reduction in early and late schizophrenia. Biol Psychiatry 2008; 63: 58-64
41 Rentzsch J, Buntebart E, Stadelmeier A. et al. Differential effects of chronic cannabis use on preattentional cognitive functioning in abstinent schizophrenic patients and healthy subjects. Schizophr Res 2011; 130: 222-227
42 Pesa N, Hermens DF, Battisti RA. et al. Delayed preattentional functioning in early psychosis patients with cannabis use. Psychopharmacology (Berl) 2012; 222: 507-518
43 Rabin RA, Zakzanis KK, George TP. The effects of cannabis use on neurocognition in schizophrenia: A meta-analysis. Schizophr Res 2011; 128: 111-116
44 Pope C, Mechoulam R, Parsons L. Endocannabinoid signaling in neurotoxicity and neuroprotection. Neurotoxicology 2010; 31: 562-571
45 Sarne Y, Asaf F, Fishbein M. et al. The dual neuroprotective-neurotoxic profile of cannabinoid drugs. Br J Pharmacol 2011; 163: 1391-1401
46 Seillier A, Advani T, Cassano T. et al. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. Int J Neuropsychopharmacol 2010; 13: 373-386
47 Spano MS, Fadda P, Frau R. et al. Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats. Eur Neuropsychopharmacol 2010; 20: 25-36
48 Leweke FM, Giuffrida A, Koethe D. et al. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use. Schizophr Res 2007; 94: 29-36
49 Schnell T, Koethe D, Daumann J. et al. The role of cannabis in cognitive functioning of patients with schizophrenia. Psychopharmacology (Berl) 2009; 205: 45-52
50 Linszen D, van Amelsvoort T. Cannabis and psychosis: An update on course and biological plausible mechanisms. Curr Opin Psychiatry 2007; 20: 116-120
51 Caspi A, Moffitt TE, Cannon M. et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005; 57: 1117-1127
52 Colizzi M, Iyegbe C, Powell J. et al. Interaction between functional genetic variation of DRD2 and cannabis use on risk of psychosis. Schizophr Bull 2015; 41: 1171-1182
53 Ho BC, Wassink TH, Ziebell S. et al. Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. Schizophr Res 2011; 128: 66-75
54 Rapp C, Bugra H, Riecher-Rössler A. et al. Effects of cannabis use on human brain structure in psychosis: A systematic review combining in vivo structural neuroimaging and post mortem studies. Curr Pharm Des 2012; 18: 5070-5080
55 Bangalore SS, Prasad KM, Montrose DM. et al Cannabis use and brain structural alterations in first episode schizophrenia–a region of interest, voxel based morphometric study. Schizophr Res 2008; 99: 1-6
56 Szeszko PR, Robinson DG, Sevy S. et al. Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. Br J Psychiatry 2007; 190: 230-236
57 Zavitsanou K, Garrick T, Huang XF. Selective antagonist [3 H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 355-360
58 Waberski TD, Kreitschmann-Andermahr I, Kawohl W. et al. Spatio-temporal source imaging reveals subcomponents of the human auditory mismatch negativity in the cingulum and right inferior temporal gyrus. Neurosci Lett 2001; 308: 107-110
59 Bossong MG, Niesink RJ. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Prog Neurobiol 2010; 92: 370-385
60 Jockers-Scherübl MC, Matthies U, Danker-Hopfe H. et al. Chronic cannabis abuse raises nerve growth factor serum concentrations in drug-naive schizophrenic patients. J Psychopharmacol 2003; 17: 439-445
61 Dubertret C, Bidard I, Adès J. et al. Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction. Schizophr Res 2006; 86: 284-290
62 Kiang M, Braff DL, Sprock J. et al. The relationship between preattentive sensory processing deficits and age in schizophrenia patients. Clin Neurophysiol 2009; 120: 1949-1957
63 Roser P, Haussleiter IS. Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies. Curr Pharm Des 2012; 18: 5141-5155
64 Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 2008; 192: 306-307